Suzetrigine
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Suzetrigine
- Molecular weight
- 473.4
- Structure (SMILES)
- COc1c([C@H]2[C@H](C(=O)Nc3ccnc(C(N)=O)c3)O[C@@](C)(C(F)(F)F)[C@H]2C)ccc(F)c1F
- journavx
- JOURNAVX
- oral suzetrigine
- suzetrigina
- Suzetrigina
- SUZETRIGINA
- suzetrigine
- Suzetrigine
- SUZETRIGINE
- Suzetrigine (SUZ)
- suzetrigine [INN]
- SUZETRIGINE [USAN]
- Suzetrigine [WHO-DD]
- suzetrigine 100mg
- suzetrigine inn
- suzetrigine usan
- suzetrigine who dd
- vrt 1737548
- VRT-1737548
- vx 548
- Vx-548
- VX-548
- vx548
- VX548
- vxc 548
And 2 more, listed on the interactive page.
- CAS registry numbers
- 2649467-58-1
- ChEMBL ID
- CHEMBL5314487
- InChIKey
- XSQUJFKRXZMOKA-PAFIKIDNSA-N
- PubChem compound IDs
- 156445116
- RxNorm IDs (RxCUI)
- 2704819
- FDA ingredient codes (UNII)
- LOG73M21H5
- Patents
- 1
- Designations
- 4
- Earliest recorded loss of exclusivity
- 4 Dec 2040
- First in class
- No
- Fast track
- Yes
- Breakthrough designation
- Yes
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- suzetrigine
- Type
- Synthetic organic
- Drug name stem
- -trigine
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Binding
- Action type
- Binding
- Target
- Nav1.8
- Gene symbol
- SCN10A
- Protein identifier
- Q9Y5Y9
- Median affinity
- 7.19
- Affinity units
- pKd
- Action
- Channel blocker
- Action type
- Channel blocker
- Target
- Nav1.8
- Gene symbol
- SCN10A
- Protein identifier
- Q9Y5Y9
- Median affinity
- 9.57
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Nav1.8
- Gene symbol
- SCN10A
- Protein identifier
- Q9Y5Y9
- Median affinity
- 8
- Affinity units
- pIC50
- Condition
- Pain
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003843
- Subject identifier
- D010146
- Condition
- Acute Pain
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003843
- Subject identifier
- D059787
- Condition
- Neuralgia
- Highest recorded phase
- 1
- Condition identifier
- EFO:0009430
- Subject identifier
- D009437
- Condition
- Diabetic Neuropathies
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000783
- Subject identifier
- D003929
- Condition identifier
- EFO_0009430
- Condition identifier
- EFO_0009806
- Highest recorded phase
- 3
- Condition identifier
- HP_0012531
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0021667
Reported adverse events
- Event
- paraesthesia
- Reports
- 5
- Reporting signal score
- 10.1968
- NCT04977336
- NCT05034952
- NCT05455502
- NCT05541471
- NCT05553366
- NCT05558410
- NCT05560464
- NCT05635110
- NCT05661734
- NCT05818852
- NCT05851157
- NCT05660538
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 2
- Polar surface area
- 103.54
- Calculated partition coefficient (ALogP)
- 3.55
- Calculated partition coefficient (XLogP)
- 3
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 33
- Molecular formula
- C21H20F5N3O4
- Monoisotopic mass
- 473.13739694
- Natural product
- No
- 51167-548
- 85766-243
- Recorded assays
- 3
- Active assays
- 3
Active assay types
- Confirmatory
Related records
Trials (47)
- A Microneurography Study of NaV1.8 Inhibition in Healthy Adults
- A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries
- A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries
- A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain
- A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
- A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty
- A Study Of Opioid Avoidance In Surgery Through Integrating Suzetrigine
- A Study of Suzetrigine (SUZ) Spray-dried Dispersion (SSD) in Healthy Adult Panelists
- A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548
- A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants
- A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin
- A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine
- A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548
- Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery
- Comparison of Suzetrigine and Oxycodone for Postoperative Pain After Primary Total Knee Arthroplasty
- Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants
- Evaluating Suzetrigine for Pain Control Following TKA
- Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
- Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty
- Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
In development for (2)
- Diabetic neuropathy Phase 2
- Neuralgia Phase 1